Human BL cell lines RAMOS, DG-75, RAJI, BJAB and DAUDI were obtained from the German Collection of Microorganisms and Cell cultures (DSMZ, Braunschweig, Germany) and BL-2, BL-30, Seraphine, BL-60, BL-70 and Salina cells were kindly provided by T. Oellerich, Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Germany. All cell lines were authenticated by STR profiling and continuously monitored for mycoplasma contamination. Cells were cultured in RPMI 1640 (Life Technologies), supplemented with 10% or 20% fetal calf serum (FCS) and 1% penicillin/streptomycin (Invitrogen). The bivalent Smac mimetic BV6 was kindly provided by Genentech. The broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) was purchased from Bachem, Necrosulfonamide (NSA) from Toronto Research Chemicals Inc., GSK’872 and Necrostatin-1s (Nec-1s) from Merck and Dabrafenib from Selleck Chemicals. Recombinant human TRAIL was obtained from R&D Systems, human recombinant TNFα from PeproTech and human multimeric FASL from AdipoGen. Doxycycline hydrochloride (DOX) was purchased from Sigma-Aldrich. LCL-161 was purchased from Novartis and AT-406, Birinapant and SGI-110 (Guadecitabine) were obtained from Selleck Chemicals. All other chemicals were purchased from Sigma-Aldrich or Carl Roth unless indicated otherwise.
Necrosulfonamide nsa
Manufactured by LGC
Necrosulfonamide (NSA) is a chemical compound used in research laboratory settings. It serves as a cell death inducer, triggering controlled cell death or apoptosis in cell cultures. NSA functions by inhibiting a specific cellular process, though its exact mechanism of action is not fully elucidated. Further details on the intended use or application of this product are not provided.
Automatically generated - may contain errors
Lab products found in correlation
Birinapant, by Selleck Chemicals (1 mentions)
Doxycycline hydrochloride dox, by Merck Group (1 mentions)
Gsk 872, by Merck Group (1 mentions)
Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions)
Rpmi 1640, by Thermo Fisher Scientific (1 mentions)
Recombinant human trail, by R&D Systems (1 mentions)
Dg 75, by Leibniz Institute DSMZ (1 mentions)
Daudi, by Leibniz Institute DSMZ (1 mentions)
Recombinant human tnf α, by Thermo Fisher Scientific (1 mentions)
Dabrafenib, by Selleck Chemicals (1 mentions)
At406, by Selleck Chemicals (1 mentions)
Lcl161, by Novartis (1 mentions)
Leptomycin b lmb, by Merck Group (1 mentions)
Gppnhp, by Merck Group (1 mentions)
Jetprime reagent, by Polyplus Transfection (1 mentions)
2 protocols using necrosulfonamide nsa
1
Characterization of Burkitt Lymphoma Cell Lines
2
Apoptosis and Necroptosis Induction Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
FADD-deficient Jurkat T cells (purchased from ATCC) were cultured in Roswell Park Memorial Institute (RPMI). HeLa cells (ECACC) and SV40 large T-immortalized MEF cells (generated in house) were cultured in Dulbecco’s modified eagle’s minimal essential medium. Both media were supplemented with 10% fetal calf serum (FCS) and l -glutamine (200 mM). Cell cultures were routinely tested for mycoplasma contamination. HeLa cells were transfected using JetPrime reagent (Polyplus transfection) according to manufacturer’s instructions. After 24 h, the cells were pre-treated for 30 min with 20 μM z-Val-Ala-DL-Asp(Ome)-fluoromethylketone (zVAD-fmk) (Bachem AG), and 2 μM BV6 (Selleck) or 10 μM TGF-β-activated kinase 1 inhibitor (TAKi) (AnalytiCon Discovery GmbH), followed by treatment with human TNF (600 lU/ml). Ten micromolar Necrostatin-1 (Nec-1) (Calbiochem, Merck) and 10 μM Necrosulfonamide (NSA) (Toronto Research chemicals) were included in the pre-treatment. Leptomycin B (LMB) (Sigma-Aldrich) was used at a concentration of 1 μM for Hela cells and 0.25 μM for FADD-deficient Jurkat cells and was added at the time of transfection or 1 h before TNF treatment or confocal imaging. GppNHp (non-hydrolyzable GTP analog, Sigma-Aldrich) was added at 1 mM 2 h before treatment or confocal imaging.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!